[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364058-105":59,"doc-detail-364058-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dll3-expression-in-neuroendocrine-carcinomas-a-comparative-analysis-across-tumor-origins","DLL3 expression in neuroendocrine carcinomas - a comparative analysis across tumor origins","","Neuroendocrine carcinomas (NECs) are rare, highly aggressive tumors with limited understanding of their underlying biology and scarce actionable diagnostic and prognostic markers. This study evaluates DLL3 prevalence and expression patterns by immunohistochemistry across multiple anatomical sites, emphasizing lung and gastroenteropancreatic (GEP) tumors. Results show high overall DLL3 expression, predominant cytoplasmic localization, and association with chromogranin A. No link emerges with proliferation index or overall survival. The findings support DLL3 as a candidate disease marker and therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dll3-expression-in-neuroendocrine-carcinomas-a-comparative-analysis-across-tumor-origins/364058/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dll3-expression-in-neuroendocrine-carcinomas-a-comparative-analysis-across-tumor-origins/364058.png","ImageObject",300,407,{"name":92,"@type":93},"LangkahRina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study on DLL3 in neuroendocrine carcinomas?","Question",{"text":112,"@type":113},"To assess DLL3 prevalence and the pattern of DLL3 expression across NECs from multiple anatomical sites, with a focus on lung and gastroenteropancreatic (GEP) tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was DLL3 expression evaluated?",{"text":117,"@type":113},"DLL3 prevalence and expression pattern were investigated using immunohistochemistry on NEC samples from different anatomical sites.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about the relationship between DLL3 and clinical outcomes?",{"text":121,"@type":113},"DLL3 levels did not significantly correlate with the tumor proliferation index or overall survival, while a correlation was observed with chromogranin A expression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364058,1790197949,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Original Research PUBLISHED 12 August 2026  \nDOI 10.3389/fendo.2026.1864568  \nOPEN ACCESS  \nEDITED BY  \nNils Lambrecht,  \nUnited States Department of Veterans Affairs, United States  \nREVIEWED BY  \nWeipang Ho,  \nLinkou Chang Gung Memorial Hospital, Taiwan  \nSuvarna Deshmukh-Rane,  \nUnited States Department of Veterans Affairs, United States  \n*CORRESPONDENCE  \nSoﬁa Dellavalle  \n soﬁ[a.dellavalle@irst.emr.it](a.dellavalle@irst.emr.it)  \n†PRESENT ADDRESS  \nAlberto Bongiovanni,  \nMedical Oncology and Haematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy  \n‡These authors have contributed equally to these work  \nRECEIVED 24 April 2026  \nREVISED 07 July 2026  \nACCEPTED 17 July 2026  \nPUBLISHED 12 August 2026  \nCITATION  \nCalabrese C, Dellavalle S, Spadazzi C, Sable B, French D, Isse K, Sharma K, Laino V, Fasano R, Tumedei MM, Pieri F, Ranallo N, Foca F, De Vita A, Miserocchi G, Cocchi C, Vanni S, Gabellone S, Cani O, Sbanchi G, Bongiovanni A and Liverani C (2026) DLL3 expression in neuroendocrine carcinomas: a comparative analysis across tumor origins.  \nFront. Endocrinol. 17:1864568 .  \ndoi: 10.3389/fendo.2026.1864568  \nCOPYRIGHT  \n© 2026 Calabrese, Dellavalle, Spadazzi, Sable, French, Isse, Sharma, Laino, Fasano, Tumedei, Pieri, Ranallo, Foca, De Vita, Miserocchi, Cocchi, Vanni, Gabellone, Cani, Sbanchi, Bongiovanni and Liverani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nDLL3 expression in  \nneuroendocrine carcinomas: a comparative analysis across tumor origins  \nChiara Calabrese 1, Soﬁa Dellavalle 1*, Chiara Spadazzi 1, Beate Sable 2, Dorothy French 2, Kumiko Isse 2,  \nKhushboo Sharma 2, Vincenzo Laino 2, Roberto Fasano 2, Maria Maddalena Tumedei 3, Federica Pieri 4, Nicoletta Ranallo 5, Flavia Foca 6, Alessandro De Vita 1, Giacomo Miserocchi 1, Claudia Cocchi 1, Silvia Vanni 1, Soﬁa Gabellone 1, Oneda Cani 1, Giulia Sbanchi 1, Alberto Bongiovanni 7†‡ and Chiara Liverani 1‡  \n1 Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, 2Amgen, Inc., Thousand Oaks, CA, United States,  \n3Advanced Cellular Therapies and Rare Tumors Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, 4 Pathology Unit, “Morgagni-Pierantoni” Hospital,  \nForlì, Italy, 5Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, 6 Biostatistics and Clinical Trial Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola FC, Italy, 7 Departmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy  \nBackground: Neuroendocrine carcinomas (NECs) are rare and highly aggressive tumors, characterized by a dismal prognosis. Their underlying biology remainsinsufﬁciently understood, highlighting an urgent need for the identiﬁcation of disease markers to enhance diagnostic and prognostic assessments, as well as to identify potential druggable targets. DLL3, an inhibitory regulator of the Notch signalling pathway, has emerged as a promising candidate in this context. Methods: We investigated DLL3 prevalence and pattern of expression in immunohistochemistry in NECs from multiple anatomical sites, with a focus on lung and gastroenteropancreatic (GEP) neoplasms.  \nResults: DLL3 was found to be highly expressed in 68 . 8% of NECs overall, with the highest prevalence observ","cbCaigSsGtleU12p","https://ap.wps.com/l/cbCaigSsGtleU12p","pdf",13915429,11,"English","# Introduction\n## Methods and study focus\n# Results\n## Expression prevalence and localization\n## Associations and survival\n# Conclusions","[{\"question\":\"What is the main goal of the study on DLL3 in neuroendocrine carcinomas?\",\"answer\":\"To assess DLL3 prevalence and the pattern of DLL3 expression across NECs from multiple anatomical sites, with a focus on lung and gastroenteropancreatic (GEP) tumors.\"},{\"question\":\"How was DLL3 expression evaluated?\",\"answer\":\"DLL3 prevalence and expression pattern were investigated using immunohistochemistry on NEC samples from different anatomical sites.\"},{\"question\":\"What did the study find about the relationship between DLL3 and clinical outcomes?\",\"answer\":\"DLL3 levels did not significantly correlate with the tumor proliferation index or overall survival, while a correlation was observed with chromogranin A expression.\"}]","DLL3 expression in neuroendocrine carcinomas - a comparative analysis across tumor origins | PDF",1790155441,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24f38fc39d18d544873165725f33724b.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acfadac504d1c3ef7dace81fb55e13e6.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a36187984263161f2cedaf4ad30dcdc.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a126b5b1d30de5e709053f6d6133bc40.webp",980,1385]